Educational Panel : Navigating Payers’ Expectations for Value-Based Agreements

feb 11, 2019: 1:30 p.m. - 2:30 p.m.
Shubert Complex

As biomedical innovation has developed advanced therapeutic modalities and prospective cures for ailments that previously had no comparable courses of treatment, the challenge of crafting sustainable reimbursement models has inspired a variety of value-based agreements. Departure from traditional dosage-based models makes it difficult for therapy developers, payers, patients, and investors to plan for a new therapy%u2019s rollout and breadth of patient access. This session will explore the early lessons from current value-based agreements to explain the payers%u2019 expectations for future models of reimbursing treatments based on outcomes versus delivery.


Moderator: Yasmeen Rahimi, Managing Director and Senior Research Analyst Biotechnology, ROTH Capital Partners


R. John Glasspool
Research Affiliate and...

Roger Longman
Founder and Chairman

Ron Philip
Chief Commercial Officer

Yasmeen Rahimi
Managing Director and ...